Filtered By:
Source: Journal of Diabetes and Its Complications
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Effects of glycemic variability and hyperglycemia in acute ischemic stroke on post-stroke cognitive impairments
We aimed to investigate the effect of glycemic variability in the acute stage of stroke on the development of post-stroke cognitive impairment (PSCI).
Source: Journal of Diabetes and Its Complications - March 28, 2018 Category: Endocrinology Authors: Jae-Sung Lim, Chulho Kim, Mi Sun Oh, Ju-Hun Lee, San Jung, Min Uk Jang, Sang-Hwa Lee, Yeo Jin Kim, Yerim Kim, Sang Won Suh, Byung-Chul Lee, Kyung-Ho Yu Source Type: research
Nutrition therapy for diabetes: Implications for decreasing cardiovascular complications
The diabetic state confers an increased risk for premature cardiovascular diseases (CVD) including myocardial infarction and ischemic stroke. Furthermore CVD is the leading cause of mortality. Potential mechanisms mediating the increased risk include dyslipidemia, hypertension, advanced glycation, a pro-coagulant diathesis, increased oxidative stress anda pro- inflammatory state.1,2
Source: Journal of Diabetes and Its Complications - July 26, 2017 Category: Endocrinology Authors: Ishwarlal Jialal, Naval Vikram Source Type: research
HbA1c in relation to incident diabetes and diabetes-related complications in non-diabetic adults at baseline
We compared the utility of glycated haemoglobin (HbA1c) and oral glucose tolerance (oGTT) in non-diabetic patients for identifying incident diabetes; all-cause mortality; cardiovascular disease (CVD) mortality; CVD, coronary heart disease (CHD), and ischaemic stroke events; and diabetes microvascular complications.Methods: Data from a New Zealand community setting were prospectively linked to hospitalization, mortality, pharmaceutical and laboratory test results data. After applying exclusion criteria (prior laboratory diagnosis or history of drug treatment for diabetes or hospitalisation for diabetes or CVD event), there ...
Source: Journal of Diabetes and Its Complications - February 19, 2017 Category: Endocrinology Authors: PA. Metcalf, C. Kyle, T. Kenealy, S. Wells, RT. Jackson Source Type: research
Diabetes and lifetime risk of stroke and subtypes in an urban middle-aged population
Lifetime risk (LTR) is defined as the cumulative probability of developing a disease in one's remaining lifetime from a given index age. The impact of diabetes on the LTR of stroke events in Asians, where stroke incidence is higher than for Westerners, has not been estimated yet. These estimates can be useful for diabetes knowledge translation activities.
Source: Journal of Diabetes and Its Complications - February 9, 2017 Category: Endocrinology Authors: Tanvir Chowdhury Turin, Tomonori Okamura, Nahid Rumana, Arfan Raheen Afzal, Makoto Watanabe, Aya Higashiyama, Yoko M Nakao, Michikazu Nakai, Misa Takegami, Kunihiro Nishimura, Yoshihiro Kokubo, Akira Okayama, Yoshihiro Miyamoto Source Type: research
Poststroke Glycemic Variability Increased Recurrent Cardiovascular Events in Diabetic Patients
Type 2 diabetes mellitus is a well-known cause of coronary artery disease,(Klein, 1995; Turner et al., 1998) stroke(Lehto et al., 1996) and peripheral artery disease, and hyperglycemia due to poor glycemic control is strongly associated with diabetic complications.(Stratton et al., 2000) Besides, as time goes on, diabetes is accompanied by greater diurnal variation of serum glucose.(Egi et al., 2007) Glycemic variability seems to have more deleterious effects than sustained hyperglycemia on the development of diabetic complications.(Ceriello et al., 2008; Monnier et al., 2006; Su et al., 2011) The wide glycemic variability...
Source: Journal of Diabetes and Its Complications - December 2, 2016 Category: Endocrinology Authors: Jee-Eun Yoon, Jun-Sang Sunwoo, Ji Sun Kim, Hakjae Roh, Moo-Young Ahn, Hee-Yeon Woo, Kyung Bok Lee Source Type: research
Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 17, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research
Moyamoya syndrome causing stroke in young women with type 1 diabetes
Moyamoya syndrome is an idiopathic brain vasculopathy characterized by stenosis of major intracranial arteries. It often presents in patients with type 1 diabetes or thyroid disease and may have an autoimmune etiology. Moyamoya-related stroke poses a diagnostic challenge as initial symptoms and deficits vary greatly from classic ischemic stroke to encephalopathy, psychiatric, or seizure disorder.
Source: Journal of Diabetes and Its Complications - August 10, 2016 Category: Endocrinology Authors: Jing W. Hughes, Jennifer A. Wyckoff, Abby S. Hollander, Colin P. Derdeyn, Janet B. McGill Tags: Case Report Source Type: research
Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes
In this study, we therefore evaluated the short-term prognostic value of early measurement of plasma copeptin levels in Chinese patients with type 2 diabetes mellitus (T2DM) and acute ischemic stroke (AIS).
Source: Journal of Diabetes and Its Complications - July 29, 2016 Category: Endocrinology Authors: Chi-Bo Wang, Miao Zong, Shi-Qing Lu, Zhuo Tian Source Type: research
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research
Comparative Risk for Cardiovascular Diseases of Dipeptidyl Peptidase-4 Inhibitors vs. Sulfonylureas in Combination with Metformin: Results of a Two-Phase Study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research
The EMPA-REG Study: What has it told us? A Diabetologist’s Perspective
EMPA-REG (1) is the first study to conclusively demonstrate that a medication developed to reduce glycemia (2) in patients with type 2 diabetes mellitus (T2DM) decreases cardiovascular events. In 7020 T2DM patients with established cardiovascular (CV) disease, empagliflozin (pooled 10 and 25 mg/day doses) significantly reduced the primary MACE outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 14% compared to placebo (HR = 0.86, 95% CI = 0.74-0.99, P=0.04 for superiority). It is noteworthy that a striking disconnect was observed between the three MACE components; (i) for nonfatal MI, the HR (=0.87) decreased s...
Source: Journal of Diabetes and Its Complications - October 21, 2015 Category: Endocrinology Authors: Ralph A. DeFronzo Source Type: research
EMPA-REG – the “diuretic hypothesis”
The two striking findings of EMPA-REG were the reduction in death (and particularly death from cardiovascular causes) and the reduction in hospitalization for heart failure.1 There was a less clear (if any) effect on events related to myocardial ischaemia (unstable angina, myocardial infarction) or atherothrombosis (myocardial infarction, stroke). I will focus on heart failure hospitalization as it may provide the key to interpretation of these extraordinary findings (and because cardiovascular mortality is harder to interpret, given the large proportion - around 40% - of deaths attributed to “other” cardiovascular cau...
Source: Journal of Diabetes and Its Complications - October 21, 2015 Category: Endocrinology Authors: Ralph A. DeFronzo, John McMurray Source Type: research
Mitigating diabetes associated ischemic stroke risk: high-risk patient identification
While the past year has brought the medical community much excitement regarding expanded therapeutic options for acute ischemic stroke treatment, Benjamin Franklin’s declaration that “an ounce of prevention is worth a pound of cure” remains a maxim of the stroke community. Emphasis on gender for patient-focused stroke prevention has evolved in response to data illustrating how gender influences age of onset, incidence, prevalence, morbidity and mortality of stroke. Notably, a large review by Appelros et al.
Source: Journal of Diabetes and Its Complications - April 23, 2015 Category: Endocrinology Authors: Casey R. Dunn, Sheryl Martin-Schild Tags: Editorial Source Type: research
Reversible Splenium Diffusion weighted MRI changes associated with hypoglycemia
Hypoglycemia can manifest with various neurologic deficits such as weakness, confusion, coma, seizures, but also focal deficits such as hemiplegia, and these symptoms can be difficult to differentiate from stroke. MRI techniques and particularly diffusion-weighted imaging (DWI) are the most useful techniques in diagnosing early ischemic injury.
Source: Journal of Diabetes and Its Complications - March 6, 2015 Category: Endocrinology Authors: A. Landais Source Type: research
